The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.
 
Charu Aggarwal
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; Lilly
Speakers' Bureau - Genentech (I); Novartis (I); Pfizer (I)
Research Funding - Genentech/Roche (Inst); Incyte (Inst); Macrogenics (Inst); Millennium (Inst); Nektar (Inst)
 
Mary Weber Redman
Consulting or Advisory Role - Bristol-Myers Squibb
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Exelixis; Genentech/Roche; Halozyme; Janssen; Novartis; PER; Pfizer; Sanofi; Turnstone Bio
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Polaris (Inst); TRACON Pharma (Inst)
 
Hossein Borghaei
Honoraria - Bristol-Myers Squibb; Celgene
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Lilly; Pfizer; Trovagene
Research Funding - Celgene (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly
 
Philip C. Hoffman
Research Funding - Novartis
 
Jeffrey D. Bradley
No Relationships to Disclose
 
Katie Griffin
No Relationships to Disclose
 
Jieling Miao
No Relationships to Disclose
 
Philip C. Mack
Honoraria - Guardant Health
Consulting or Advisory Role - Apton Biosystems; AstraZeneca; MolecularMD; Novartis
Research Funding - Boehringer Ingelheim
Travel, Accommodations, Expenses - Guardant Health
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - ARIAD; AstraZeneca; Biothera; Clovis Oncology; Genentech; Genentech; Gensignia Life Sciences; Janssen; Lilly; Merck
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Roy S. Herbst
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Lilly; Merck; Pfizer
Research Funding - Genentech; Merck
 
Karen Kelly
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - ARIAD; ARIAD; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; G1 Therapeutics; Genentech/Roche; Lilly; Lilly; Synta
Research Funding - Abbvie (Inst); Celgene (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Millennium (Inst); Novartis (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Roche
 
David R. Gandara
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Celgene; Clovis Oncology; Genentech; Guardant Health; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; Response Genetics; Sanofi; Synta
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)